Why The Mylan 'Love Triangle' Could Benefit Investors

$30 billion proposal to buy

could entail a sort of love triangle with benefits for investors, an analyst said Monday. The proposal, disclosed April 8, may spur

to step up with an offer to buy Mylan, according to JP Morgan's Christopher Schott. Investors should take positions in all three companies, with a mix weighted to Mylan, in Schott's view. Schott likened circumstances to

10-month bidding war for

, which it lost to

in November. Shares of all three companies rose substantially in 2014. Mylan is "the best positioned" among the three companies, given the likelihood of either its acquisition of Perrigo or its acquisition by Teva, in Schott's view. Perrigo's potential acquisition by Mylan makes it attractive, with "little downside risk" should the deal fall through, Scott said. Teva, meanwhile, has the potential for a "value-enhancing transaction," either a deal with Mylan or another, larger company, Schott said. Citing a "dynamic M&A environment," Schott raised his price target on Mylan 14 percent to $80; on Perrigo by 19 percent to $215 and on Teva by 7.7 percent to $70. Schott maintained Overweight ratings on both Mylan and Perrigo, and a Neutral rating on Teva.